vTv Therapeutics (VTVT) Net Income towards Common Stockholders (2014 - 2026)

vTv Therapeutics has disclosed Net Income towards Common Stockholders across 13 years of filings, most recently posting -$13.1 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 115.91% year-over-year to -$13.1 million; the TTM figure through Jun 2026 stood at -$4.8 million (up 75.68% YoY), while the FY2025 annual figure was -$27.0 million, down 46.11% from the prior year.
• Net Income towards Common Stockholders came in at -$13.1 million for Q2 2026 at vTv Therapeutics, down from $24.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $24.1 million in Q1 2026 to a low of -$13.1 million in Q2 2026.
• Average Net Income towards Common Stockholders over 5 years is -$4.1 million, with a median of -$5.0 million recorded in 2024.
• Year-over-year, Net Income towards Common Stockholders sank 418.26% in 2022 and jumped 573.96% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at -$4.7 million in 2022, then advanced by 26.7% to -$3.5 million in 2023, then slipped by 4.49% to -$3.6 million in 2024, then plunged by 96.42% to -$7.1 million in 2025, then plunged by 82.88% to -$13.1 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$13.1 million in Q2 2026, $24.1 million in Q1 2026, and -$7.1 million in Q4 2025.